ijms-logo

Journal Browser

Journal Browser

Cancer Stem Cells 2022–2023

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 3288

Special Issue Editor

Special Issue Information

Dear Colleagues,

Cancer stem cells (CSCs) or tumour initiating cells are subpopulations of cancer cells that show similar characteristics to normal stem cells. Cancer is a heterogeneous disease that promotes cell growth, disables cell death mechanisms, and evades immune surveillance and therapy. CSCs are shown to be involved in tumour initiation, poor prognosis and metastasis as well as therapy resistance. In this Special Issue of IJMS, our objective is to explore the current state-of-art in our understanding of the mechanisms underpinning CSC biology contributing to tumour heterogeneity, cancer aetiology and treatment. Potential topics include: molecular mechanisms driving CSC plasticity; interaction with tumour microenviroment; immune evasion; viability and self-renewal; stemness related cell signalling and therapy resistance. Authors are invited and welcome to submit original research papers, reviews, and short communications.

Dr. Pinar Uysal Onganer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer stem cells
  • tumour initiating cells
  • apoptosis
  • cell signalling
  • angiogenesis
  • metastasis
  • stemness markers
  • metastasis
  • therapy resistance

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 2609 KiB  
Article
TRIM28 Is a Novel Regulator of CD133 Expression Associated with Cancer Stem Cell Phenotype
by Yan S. Kim, Daria M. Potashnikova, Alisa M. Gisina, Irina V. Kholodenko, Arthur T. Kopylov, Olga V. Tikhonova, Leonid K. Kurbatov, Aleena A. Saidova, Anna V. Tvorogova, Roman V. Kholodenko, Pavel V. Belousov, Ivan A. Vorobjev, Victor G. Zgoda, Konstantin N. Yarygin and Alexey Yu. Lupatov
Int. J. Mol. Sci. 2022, 23(17), 9874; https://doi.org/10.3390/ijms23179874 - 30 Aug 2022
Cited by 4 | Viewed by 2302
Abstract
CD133 is an extensively studied marker of the most malignant tumor cell population, designated as cancer stem cells (CSCs). However, the function of this glycoprotein and its involvement in cell regulatory cascades are still poorly understood. Here we show a positive correlation between [...] Read more.
CD133 is an extensively studied marker of the most malignant tumor cell population, designated as cancer stem cells (CSCs). However, the function of this glycoprotein and its involvement in cell regulatory cascades are still poorly understood. Here we show a positive correlation between the level of CD133 plasma membrane expression and the proliferative activity of cells of the Caco-2, HT-29, and HUH7 cancer cell lines. Despite a substantial difference in the proliferative activities of cell populations with different levels of CD133 expression, transcriptomic and proteomic profiling revealed only minor distinctions between them. Nonetheless, a further in silico assessment of the differentially expressed transcripts and proteins revealed 16 proteins that could be involved in the regulation of CD133 expression; these were assigned ranks reflecting the apparent extent of their involvement. Among them, the TRIM28 transcription factor had the highest rank. The prominent role of TRIM28 in CD133 expression modulation was confirmed experimentally in the Caco2 cell line clones: the knockout, though not the knockdown, of the TRIM28 gene downregulated CD133. These results for the first time highlight an important role of the TRIM28 transcription factor in the regulation of CD133-associated cancer cell heterogeneity. Full article
(This article belongs to the Special Issue Cancer Stem Cells 2022–2023)
Show Figures

Figure 1

Back to TopTop